{
    "doi": "https://doi.org/10.1182/blood.V108.11.4999.4999",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=681",
    "start_url_page_num": 681,
    "is_scraped": "1",
    "article_title": "Influence of Renal Failure on the Osteoprotegerin Level in Patients with Multiple Myeloma. ",
    "article_date": "November 16, 2006",
    "session_type": "Abstracts Not Selected for Presentation",
    "topics": [
        "kidney failure",
        "multiple myeloma",
        "tumor necrosis factor receptor 11b",
        "bone diseases",
        "bone lesion",
        "kidney diseases",
        "neoplasms",
        "uremia",
        "enzyme-linked immunosorbent assay",
        "mann-whitney u test"
    ],
    "author_names": [
        "Stefcho Goranov, PhD, DM",
        "Veselina Goranova-Marinova",
        "Emil Kumchev, PhD",
        "Pavel Pavlov",
        "Todorka Tzvetkova, PhD, DM"
    ],
    "author_affiliations": [
        [
            "Clinic of Hematology, University Hospital \u201cSv. Georgi\u201d",
            " "
        ],
        [
            "Clinic of Hematology, University Hospital \u201cSv. Georgi\u201d",
            " "
        ],
        [
            "Clinic of Nephrology",
            " "
        ],
        [
            "Central Clinical Laboratory, Plovdiv, Bulgaria",
            " "
        ],
        [
            "Central Clinical Laboratory, Plovdiv, Bulgaria",
            " "
        ]
    ],
    "first_author_latitude": "37.599999999999994",
    "first_author_longitude": "-95.665",
    "abstract_text": "The aim of the study is to analyse the osteoprotegerin (OPG) level in patients with multiple myeloma (MM), primary renal diseases with renal failure (PRD with RF) and healthy controls and to assess the influence of RF on the correlations of OPG with basic parameters for MM. Serum levels of OPG (ELISA kits, Biomedica, Vienna) were studied in 66 newly diagnosed patients with MM, 51 with PRD and RF and 32 controls. In MM patients OPG is presented also as OPG/creatinin ratio and is studied acc to the clinical stage (Durie and Salmon), bone marrow infiltration, grade of myeloma bone disease (MBD) using the Merlini scale, b2-microglobulin and LDH. Statistics were done by SPSS v 11.0 (variative, alternative, correlative, non-parametric analyses, Mann-Whitney test, one-way ANOVA; at p0,05. In patients with PRD OPG is significantly higher in II gr. RF (p6,0pmol/l is about 2,5 times higher (68,7%) than the proportion of patients with low OPG<3,44pmol/l (25,0%), p<0,05. MM patients with minimal and no bone lesions+RF have significantly higher OPG than these with severe MBD + RF (9,97 \u00b1 2,42 vs 4,92 \u00b1 0,62 pmol/l, p<0,05). The correlations of OPG are stronger for OPG/creatinin and are most expressed in the MM group without RF. RF \u201cmasques\u201d the clinical correlations of OPG (tabl.2). OPG levels in MM show phase dynamics: initial elevation in early clinical stages and low grade bone lesions (successful counteraction to intensive bone resorbtion) followed by decrease in the advanced stages and severe MBD. These data we explain with the combined but opposite effects of RF (elevates OPG providing skeletal resistance in uremia) and the specific, not-possible-to overcome action of myeloma tumor burden (directly degrades OPG and inhibits osteoblast function). OPG levels in patients with MM, PRD and controls  Groups . N . OPG pmol/l mean\u00b1SEM . P . *vs controls Controls 32 3,77 \u00b1 0,33 0,01 MM 66 5,36\u00b1 0,45  MM without RF 39 4,51 \u00b1 0,30 0,001 MM with RF 27 6,60 \u00b1 1,00  MM with I gr RF (cr 166\u2013353 mol/l) \u03bc 18 6,73 \u00b1 1,37 NS MM with II gr RF (cr 353\u2013 707 mol/l) \u03bc 9 6,20 \u00b1 1,32  PRD with RF 51 5,74\u00b1 0,36 0,001* PRD with I gr RF 23 4,50\u00b1 0,32 0.02 PRD with II gr RF 28 6,75\u00b1 0,51  Groups . N . OPG pmol/l mean\u00b1SEM . P . *vs controls Controls 32 3,77 \u00b1 0,33 0,01 MM 66 5,36\u00b1 0,45  MM without RF 39 4,51 \u00b1 0,30 0,001 MM with RF 27 6,60 \u00b1 1,00  MM with I gr RF (cr 166\u2013353 mol/l) \u03bc 18 6,73 \u00b1 1,37 NS MM with II gr RF (cr 353\u2013 707 mol/l) \u03bc 9 6,20 \u00b1 1,32  PRD with RF 51 5,74\u00b1 0,36 0,001* PRD with I gr RF 23 4,50\u00b1 0,32 0.02 PRD with II gr RF 28 6,75\u00b1 0,51  View Large Correlation coefficients of OPG in MM and eliminating the influence of renal function  Parameter . OPG pmol/l . OPG/creatinin . OPG pmol/l (without RF) . . p . r . p . r . p . r . Clinical stage <0,05 \u22120,275 <0,001 \u22120,616 <0,001 \u2212 0,669 MBD <0,05 \u22120,323 <0,001 \u22120,521 <0,001 \u2212 0,556 m. infiltration N.S.  <0,001 \u22120,530 <0,001 \u2212 0,562 \u00df 2 -microglobulin <0,05 +0,375 N.S  N.S  LDH N.S  N.S  <0,05 \u22120,338 Parameter . OPG pmol/l . OPG/creatinin . OPG pmol/l (without RF) . . p . r . p . r . p . r . Clinical stage <0,05 \u22120,275 <0,001 \u22120,616 <0,001 \u2212 0,669 MBD <0,05 \u22120,323 <0,001 \u22120,521 <0,001 \u2212 0,556 m. infiltration N.S.  <0,001 \u22120,530 <0,001 \u2212 0,562 \u00df 2 -microglobulin <0,05 +0,375 N.S  N.S  LDH N.S  N.S  <0,05 \u22120,338 View Large"
}